Table 3.
Timing of KRAS test within the course of mCRC diagnosis and treatment among patients who received KRAS testing.
| N (%) Tested | ||||||
|---|---|---|---|---|---|---|
| Year of mCRC diagnosis | Before mCRC diagnosis | At mCRC diagnosis (<90 days) | Between diagnosis and treatment1 | Before treatment1 (<90 days) | After treatment1 initiated | Total |
| 2006 | 2 (6%) | 3 (9%) | 3 (9%) | 13 (38%) | 15 (44%) | 34 |
| 2007 | 3 (5%) | 4 (7%) | 14 (24%) | 16 (27%) | 23 (39%) | 59 |
| 2008 | 3 (5%) | 19 (31%) | 13 (21%) | 21 (34%) | 12 (19%) | 62 |
| 2009 | 3 (12%) | 13 (50%) | 4 (15%) | 9 (35%) | 3 (12%) | 26 |
1
treatment with EGFR inhibitors. Includes those tested but not yet treated.
*
KRAS test dates are unknown for 71 participants